FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency By Ogkologos - February 18, 2026 288 0 Facebook Twitter Google+ Pinterest WhatsApp Patients should be tested for genetic variants of DPYD prior to initiating treatment Source RELATED ARTICLESMORE FROM AUTHOR Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Metastatic Breast Cancer: ESMO Living Guideline EMA Recommends Extension of Indications for Datopotamab Deruxtecan MOST POPULAR Breast Cancer Patient Given 2 Years to Live is Now a... May 28, 2021 European Lung Cancer Virtual Congress 2021, 25-27 March [Event Announcement] March 12, 2021 Efficacy of Tivozanib Monotherapy in the Post-ICI Setting Among Patients with... October 9, 2024 5-Year-Old Boy Meets Generous Stem Cell Donor Who Cured Him October 13, 2021 Load more HOT NEWS Breast Cancer Survivors in Happy Romantic Relationships Are Healthier, Study Says A recipe for hydration! The Frontline Oncology Workforce Unites to Reduce the Burden of Cancer... Ending smoking could more than halve England’s cancer inequality gap
